KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Buildings (2016 - 2022)

Bio-Rad Laboratories (BIO) has disclosed Buildings for 14 consecutive years, with $393.6 million as the latest value for Q4 2022.

  • Quarterly Buildings rose 2.03% to $393.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $393.6 million through Dec 2022, up 2.03% year-over-year, with the annual reading at $393.6 million for FY2022, 2.03% up from the prior year.
  • Buildings for Q4 2022 was $393.6 million at Bio-Rad Laboratories, up from $385.8 million in the prior quarter.
  • The five-year high for Buildings was $393.6 million in Q4 2022, with the low at $331.6 million in Q4 2018.
  • Average Buildings over 5 years is $363.1 million, with a median of $363.0 million recorded in 2020.
  • The sharpest move saw Buildings grew 6.28% in 2020, then increased 2.03% in 2022.
  • Over 5 years, Buildings stood at $331.6 million in 2018, then grew by 3.03% to $341.6 million in 2019, then increased by 6.28% to $363.0 million in 2020, then grew by 6.27% to $385.8 million in 2021, then increased by 2.03% to $393.6 million in 2022.
  • According to Business Quant data, Buildings over the past three periods came in at $393.6 million, $385.8 million, and $363.0 million for Q4 2022, Q4 2021, and Q4 2020 respectively.